Metabolomic Profiling in Neuromyelitis Optica Spectrum Disorder Biomarker Discovery.

There is no specific test for diagnosing neuromyelitis optica spectrum disorder (NMOSD), a disabling autoimmune disease of the central nervous system. Instead, diagnosis relies on ruling out other related disorders with overlapping clinical symptoms. An urgency for NMOSD biomarker discovery is underscored by adverse responses to treatment following misdiagnosis and poor prognosis following the delayed onset of treatment.

Kidney Function After the First Kidney Stone Event.

Objective: To determine whether there is a persistent decline in kidney function after the first kidney stone event.

Patient And Methods: Incident symptomatic stone formers and age- and sex-matched controls underwent 2 study visits 90 days apart to assess kidney function, complete a survey, and have their medical records reviewed. Kidney function was compared between stone formers and controls adjusting for clinical, blood, and urine risk factors.